
|Articles|August 15, 2003
Novartis to market antibody fragment
Basel, Switzerland-Novartis Ophthalmics will have exclusive license to develop and market ranibizumab (Lucentis, formerly known as rhuFab V2), an anti-VEGF antibody fragment, outside North America under a new agreement with Genentech Inc.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Treating myopia today: US-focused treatments, challenges, and global insights
2
US FDA awards Epion Therapeutics EpiSmart cross-linking system Fast Track designation
3
FDA clears BVI’s FineVision HP trifocal IOL for the US market
4
Abeona Therapeutics’ ABO-503 chosen for FDA's Rare Disease Endpoint Advancement Pilot Program
5